SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CEPH
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: victor gupta who wrote (49)1/25/1997 12:01:00 AM
From: Mark Nelson   of 998
 
Victor, NeuroInvestment has had a $50 target on CEPH since at least 7/96. The following press says it's a "year end target".

Cephalon had been recommended by NeuroInvestment from July 1995 through December 1995, when it was deleted from the Recommended list. It is being recommended again based on the likelihood of favorable action from the June 7 FDA hearing for Myotrophin, which represents a dramatically accelerated review of that drug for the treatment of ALS. NeuroInvestment does not agree with the few analysts that have concluded that Myotrophin has not shown clinical effectiveness; the U.S Phase III trials did indeed show significant efficacy. The Advisory Committee reviewing it is the same committee that reviewed and approved Rilutek for ALS, thus the strong likelihood is for approval, and a quick move in the stock price to at least 35. Though the Company will have to absorb the costs of buying out the Limited Partners who have supplied much of Myotrophin's financing, the pipeline is strong and they are about to file another NDA for Modafinil. If the FDA acts as is expected, Cephalon will then move into the first tier of companies, those with near term revenue potential. The year-end target for Cephalon is 50.

I expect to hear good news soon re: Modafinil for narcolepsy. NDA was filed the first week of January. It has "orphan drug status". I'd like to think that that will somehow expidite the review.

Onward...
Mark
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News